Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2001

View Archived Issues

Graft material for oral mucosal defects

Orion and Pharmacia agree to develop antianxiety treatment for the U.S. market

CollaGenex to market dental products from Atrix in the U.S.

CV Therapeutics and Incyte advance cardiovascular genomics collaboration

Avant replies to FDA's clinical hold of TP-10

Novel inhibitors of human CD23 and TNF release reported by GSK

Four centers added to Neotrofin Parkinson's disease trial

PH-10 enters phase I study for treatment of actininc keratosis

OSI Pharmaceuticals updates Tarceva development

Exisulind reduces adenomatous colon polyps in clinical trial

Virax to develop prostate cancer immunotherapy

More data reported for BMP delivery systems

Adult skin as a source of multipotent stem cells

NeoGenesis to develop drug leads for Mitsubishi-Tokyo Pharmaceuticals

BTG takes over development of oral vaccine delivery technology

Affymetrix and Orchid broaden genetic technology alliance

Positive phase II results reported for PhotoCure's Hexvix diagnostic

Pharmacia presents antiherpesvirus agents with outstanding activity at ACS

Corgentech cleared by FDA to begin phase III trial of E2F decoy

NeuroSearch cleared to begin phase I studies of potential sickle cell disease treatment in U.S.

ImmunoGen highlights significant events over past year

GSK describes NPY Y5 antagonists and their effect on food intake

Banyu describes first M3 antagonist with high selectivity over other muscarinic subtypes

Meiji Seika discloses new antineoplastics isolated from fungus

Dual angiotensin/endothelin receptor antagonists reported by BMS

CRF antagonists added to DuPont patent portfolio

Research at Nippon Shinyaku leads to new antitumor compounds

Novel DMARDs reported by Sumitomo during the ACS meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...